Seed · 2026-11-09 · Healthcare
SRTD Biotech raises $34.0M
62
AI Score
Amount
$34.0M
Round
Seed
Lead
Mérieux Equity Partners
HQ
Jülich, DE
Why it matters: The round shows investors backing selective mRNA expression as a way around the field's healthy-tissue toxicity problem, and names the syndicate behind it.
Jülich-based SRTD Biotech closed an oversubscribed €31.5M seed round led by Mérieux Equity Partners.
- Participants:
- NRW.BANK, Boehringer Ingelheim Venture Fund, Lilly Ventures, HTGF, Anobis Asset
- Source:
- EU-Startups ↗ · Midu summary
Deal Dossier PRO
Pro feature
Deal Dossier for SRTD Biotech
Company, lead and participating investors, founders, and verified public contact channels — sourced, generated on demand.
Generate dossier — ProFigures marked company-reported are unaudited. Not investment advice. Request a correction or removal (team@midu.si).
Recent Healthcare rounds
Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing